$0.53 Earnings Per Share Expected for West Pharmaceutical Services, Inc. (WST) This Quarter
Wall Street analysts expect West Pharmaceutical Services, Inc. (NYSE:WST) to report earnings per share (EPS) of $0.53 for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for West Pharmaceutical Services’ earnings. The lowest EPS estimate is $0.53 and the highest is $0.54. West Pharmaceutical Services also reported earnings of $0.53 per share during the same quarter last year. The business is scheduled to report its next earnings report on Thursday, October 26th.
On average, analysts expect that West Pharmaceutical Services will report full-year earnings of $2.68 per share for the current financial year, with EPS estimates ranging from $2.66 to $2.69. For the next fiscal year, analysts expect that the business will post earnings of $2.90 per share, with EPS estimates ranging from $2.80 to $3.00. Zacks’ EPS averages are an average based on a survey of analysts that cover West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The business had revenue of $397.60 million during the quarter, compared to analyst estimates of $406.00 million. During the same period in the previous year, the business posted $0.59 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 2.5% on a year-over-year basis.
WST has been the subject of several research analyst reports. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 target price for the company in a research report on Friday, June 9th. Stephens started coverage on West Pharmaceutical Services in a report on Tuesday. They issued an “equal weight” rating and a $99.00 price target on the stock. BidaskClub cut West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Finally, Jefferies Group LLC upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their price target for the stock from $96.00 to $115.00 in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $107.33.
Several institutional investors and hedge funds have recently added to or reduced their stakes in WST. American Century Companies Inc. increased its holdings in shares of West Pharmaceutical Services by 0.4% in the second quarter. American Century Companies Inc. now owns 701,364 shares of the medical instruments supplier’s stock worth $66,293,000 after purchasing an additional 2,605 shares during the last quarter. CIBC Asset Management Inc purchased a new stake in shares of West Pharmaceutical Services in the second quarter worth about $223,000. Chatham Capital Group Inc. lifted its position in shares of West Pharmaceutical Services by 7.8% in the second quarter. Chatham Capital Group Inc. now owns 17,300 shares of the medical instruments supplier’s stock worth $1,635,000 after buying an additional 1,245 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of West Pharmaceutical Services by 16.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 88,252 shares of the medical instruments supplier’s stock worth $8,342,000 after buying an additional 12,609 shares in the last quarter. Finally, Prudential Financial Inc. lifted its position in shares of West Pharmaceutical Services by 149.6% in the second quarter. Prudential Financial Inc. now owns 400,270 shares of the medical instruments supplier’s stock worth $37,834,000 after buying an additional 239,906 shares in the last quarter. 90.57% of the stock is owned by institutional investors and hedge funds.
West Pharmaceutical Services (NYSE:WST) traded down 0.67% during trading on Wednesday, reaching $93.99. 25,663 shares of the company’s stock were exchanged. The company has a market cap of $6.96 billion, a P/E ratio of 40.34 and a beta of 1.12. The stock’s 50-day moving average is $90.36 and its 200-day moving average is $90.56. West Pharmaceutical Services has a 12-month low of $70.17 and a 12-month high of $99.91.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be issued a $0.14 dividend. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s payout ratio is currently 22.22%.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.